Lipocalin 2 stimulates bone fibroblast growth factor 23 production in chronic kidney disease

查看全文 作　　者：Guillaume [1]Courbon;Connor [1]Francis;Claire [1]Gerber;Samantha [1]Neuburg;Xueyan [1]Wang;Emily [1]Lynch;Tamara [1]Isakova;Jodie [2]LBabitt;Myles [3]Wolf;Aline [1]Martin;Valentin [1]David

机构地区：[1]Division of Nephrology and Hypertension,Department of Medicine,and Center for Translational Metabolism and Health,Institute for Public Health and Medicine,Northwestern University Feinberg School of Medicine,Chicago,IL,USA;[2]Nephrology Division,Program in Membrane Biology,Massachusetts General Hospital,Harvard Medical School,Boston,MA,USA;[3]Division of Nephrology,Department of Medicine,and Duke Clinical Research Institute,Duke University School of Medicine,Durham,NC,USA

出　　处：《Bone Research》索引2021年第9卷第3期,共11页

基　　金：supported by grants from the National Institute of Health to V.D.(R01DK102815,R01DK114158);A.M.(R01DK101730). 摘　　要：Bone-produced fibroblast growth factor 23(FGF23)increases in response to inflammation and iron deficiency and contributes to cardiovascular mortality in chronic kidney disease(CKD).Neutrophil gelatinase-associated lipocalin(NGAL or lipocalin 2;LCN2 the murine homolog)is a pro-inflammatory and iron-shuttling molecule that is secreted in response to kidney injury and may promote CKD progression.We investigated bone FGF23 regulation by circulating LCN2.At 23 weeks,Col4a3KO mice showed impaired kidney function,increased levels of kidney and serum LCN2,increased bone and serum FGF23,anemia,and left ventricular hypertrophy(LVH).Deletion of Lcn2 in CKD mice did not improve kidney function or anemia but prevented the development of LVH and improved survival in association with marked reductions in serum FGF23.Lcn2 deletion specifically prevented FGF23 elevations in response to inflammation,but not iron deficiency or phosphate,and administration of LCN2 increased serum FGF23 in healthy and CKD mice by stimulating Fgf23 transcription via activation of cAMP-mediated signaling in bone cells.These results show that kidney-produced LCN2 is an important mediator of increased FGF23 production by bone in response to inflammation and in CKD.LCN2 inhibition might represent a potential therapeutic approach to lower FGF23 and improve outcomes in CKD. 关键词：FGF23 KIDNEY INFLAMMATION

相关文献

参考文献（64）
引证文献（7）
耦合文献（6）

参考文献(64)

引证文献(7)

耦合文献(6)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Lipocalin 2 stimulates bone fibroblast growth factor 23 production in chronic kidney disease

参考文献(64)

引证文献(7)

耦合文献(6)

用户提示